Short answer
Terns Pharmaceuticals, Inc. (TERN) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 8.01 (Other Events). Merck acquisition completed May 5, 2026, with Terns surviving as Merck’s wholly owned subsidiary.
- This filing includes Item 3.01, an item that often signal trouble.
Terns Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merck acquisition completed May 5, 2026, with Terns surviving as Merck’s wholly owned subsidiary
- 100,091,794 shares tendered, representing approximately 86.36% of outstanding shares
- Merger completed under Delaware Section 251(h) without a stockholder vote, accelerating transaction close
- Outstanding shares converted into cash at the Offer Price, subject to tax withholding
- In-the-money options and RSUs converted to cash; out-of-the-money options cancelled without consideration
Item 3.01 · Notice of Delisting
- Terns’ shares expected delisted from Nasdaq after Merger consummation
- Trading suspension expected before market open May 5, 2026
- Nasdaq expected to file Form 25 with SEC on May 5, 2026
- Form 15 filing intended to terminate registration and suspend SEC reporting obligations
Item 3.03 · Material Modification to Rights of Security Holders
- Rights impact tied to disclosed transaction, leadership changes, and charter amendments in Items 2.01, 5.02, and 5.03
- Investors should review those sections for control, governance, and security-holder implications
Item 5.01 · Changes in Control of Registrant
- Merck Parent’s 364-day delayed-draw term loan credit agreement supports financing for the transaction
- Citibank, N.A. serves as administrative agent for the lender group
- Short-dated financing structure introduces refinancing and execution risk for the control change
Item 5.02 · Departure/Election of Directors or Officers
- Merger completion removed all seven incumbent Terns directors, including Robert Azelby and Jeffrey Kindler
- Purchaser directors Jon Filderman, Melissa Leonard and Dalton Smart became directors of the surviving corporation
- All incumbent Terns officers departed at closing, replaced by Purchaser’s officers
- Leadership turnover confirms operational control transferred to the acquiring party through the merger
- New leadership biographies and roles appear in Schedule I to Merck’s April 7, 2026 Schedule TO
Item 8.01 · Other Events
- Merck Parent completed transactions under the Merger Agreement on May 5, 2026
- Closing marks execution of the announced merger, making its terms effective for Terns shareholders
- Exhibit 99.1 contains Merck Parent’s closing announcement and transaction details
Other items in this filing:
- Item 5.03: Amendments to Articles of Incorporation or Bylaws
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Terns Pharmaceuticals, Inc. 8-K filings
Get the next TERN 8-K as it lands
Follow TERN for push alerts, or ask the research agent what this filing means.